Disulfiram
- Generic Name
- Disulfiram
- Brand Names
- Antabuse
- Drug Type
- Small Molecule
- Chemical Formula
- C10H20N2S4
- CAS Number
- 97-77-8
- Unique Ingredient Identifier
- TR3MLJ1UAI
- Background
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nau...
- Indication
For the treatment and management of chronic alcoholism
- Associated Conditions
- Chronic Alcoholism
- Associated Therapies
- -
Disulfiram as a Modulator of Amyloid Precursor Protein-processing
- Conditions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 17
- Registration Number
- NCT03212599
Bioavailability of Disulfiram and Metformin in Glioblastomas
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Target Recruit Count
- 3
- Registration Number
- NCT03151772
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Daniel George, MD
- Target Recruit Count
- 9
- Registration Number
- NCT02963051
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 10
- Registration Number
- NCT02770378
- Locations
- 🇩🇪
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany
Neural Mechanisms of Disulfiram Effects
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 7
- Registration Number
- NCT02735577
- Locations
- 🇺🇸
NYPInstitute, New York, New York, United States
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 35
- Registration Number
- NCT02715609
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Disulfiram in Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Target Recruit Count
- 88
- Registration Number
- NCT02678975
- Locations
- 🇸🇪
Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
🇸🇪Ryhov County Hospital, Jönköping, Sweden
🇸🇪Linköping University Hospital, Linkoping, Sweden
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 16
- Registration Number
- NCT02671890
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States
A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Registration Number
- NCT02134002
- Locations
- 🇫🇷
Paul Brousse Hospital, Villejuif, France
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT01944371
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Australia
🇺🇸San Francisco General Hospital, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.